NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $24.95 -0.09 (-0.37%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Veracyte Stock (NASDAQ:VCYT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Veracyte alerts:Sign Up Key Stats Today's Range$24.53▼$25.6050-Day Range$24.00▼$52.5252-Week Range$21.91▼$60.91Volume1.55 million shsAverage Volume1.31 million shsMarket Capitalization$2.01 billionP/E Ratio16.13Dividend YieldN/APrice Target$44.50Consensus RatingHold Company Overview Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease. Founded in 2008 and headquartered in South San Francisco, California, Veracyte serves clinicians and patients in the United States and makes certain products available in international markets. Marc Stapley is the company’s chief executive officer.AI Generated. May Contain Errors. Read More Veracyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreVCYT MarketRank™: 3.300013693 of 5 starsVeracyte scored higher than 66% of companies evaluated by MarketBeat, and ranked 248th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingVeracyte has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on no strong buy ratings, 6 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialVeracyte has a consensus price target of $44.50, representing about 74.3% upside from its current price of $25.53.Amount of Analyst CoverageVeracyte has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Veracyte's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-13.43% Earnings GrowthEarnings for Veracyte are expected to decrease by -13.43% in the coming year, from $1.34 to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is 16.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is 16.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.62.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.08% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 8.22.Change versus previous monthShort interest in Veracyte has recently decreased by 2.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentVeracyte has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Veracyte this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows4 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,858,904.00 in company stock.Percentage Held by Insiders1.60% of the stock of Veracyte is held by insiders.Percentage Held by InstitutionsVeracyte has minimal institutional ownership at this time.Read more about Veracyte's insider trading history. Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCYT Stock News HeadlinesVeracyte (NASDAQ:VCYT) Stock Gets Price Target Reduction from StephensNovember 14, 2026 | americanbankingnews.comVeracyte Earnings Call Highlights Growth and CautionNovember 13, 2026 | tipranks.comEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.November 20 at 1:00 AM | Pennie Financial (Ad)Veracyte: Solid Profits, Slowing Tests, And A Stock In LimboNovember 12, 2026 | seekingalpha.comVeracyte (VCYT) Securities Investigation Notice - Levi & KorsinskyNovember 12, 2026 | prnewswire.comVeracyte (NASDAQ:VCYT) Stock Price Target Cut by Piper SandlerNovember 12, 2026 | americanbankingnews.comUBS Group Issues Pessimistic Forecast for Veracyte (NASDAQ:VCYT) Stock PriceNovember 11, 2026 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Stock: Insider Jens Holstein Sells 7,500 SharesOctober 29, 2026 | insidertrades.comSee More Headlines VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $42.10 at the beginning of the year. Since then, VCYT stock has decreased by 39.3% and is now trading at $25.5340. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported $0.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.10. The firm's revenue for the quarter was up 15.1% compared to the same quarter last year. Read the conference call transcript. Does Veracyte have any subsidiaries? Veracyte subsidiaries include these companies: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. When did Veracyte IPO? Veracyte (VCYT) raised $70 million in an initial public offering on Wednesday, October 30th 2013. The company issued 5,000,000 shares at $13.00-$15.00 per share. Who are Veracyte's major shareholders? Top institutional shareholders of Veracyte include State Street Corp (6.86%), William Blair Investment Management LLC (3.37%), GW&K Investment Management LLC (3.00%) and Goldman Sachs Group Inc. (2.78%). Insiders that own company stock include Marc Stapley, Rebecca Chambers, Phillip G Febbo, Annie Mcguire, John Leite, Robert S Epstein, Jonathan Wygant, Jonathan Wygant, Muna Bhanji, Evan/ Fa Jones, Jens Holstein and Karin Eastham. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Micron Technology (MU), Block (XYZ), Advanced Micro Devices (AMD), Tesla (TSLA) and Invitae (NVTA). Company Calendar Last Earnings11/04/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, VCYT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VCYT CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees755Year Founded2008Price Target and Rating Average Price Target for Veracyte$44.50 High Price Target$65.00 Low Price Target$30.00 Potential Upside/Downside+77.8%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$1.55 Trailing P/E Ratio16.17 Forward P/E Ratio21.58 P/E GrowthN/ANet Income$66.35 million Net Margins21.80% Pretax Margin20.33% Return on Equity8.99% Return on Assets8.34% Debt Debt-to-Equity RatioN/A Current Ratio5.56 Quick Ratio5.25 Sales & Book Value Annual Sales$517.15 million Price / Sales3.91 Cash Flow$1.46 per share Price / Cash Flow17.17 Book Value$17.76 per share Price / Book1.41Miscellaneous Outstanding Shares80,690,000Free Float79,404,000Market Cap$2.02 billion OptionableOptionable Beta1.98 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:VCYT) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our Partners$85.7 billion from the SpaceX IPO, and where it may go nextA stock trading under $1 could announce a supply deal with Elon Musk. Similar partnership announcements have s...Brownstone Research | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.